Transcription regulatory polymorphism −43T>C in the 5′-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy

2007 ◽  
Vol 27 (11) ◽  
pp. 1057-1061 ◽  
Author(s):  
Anthoula Chatzikyriakidou ◽  
Ioannis Georgiou ◽  
Paraskevi V. Voulgari ◽  
Christos G. Papadopoulos ◽  
Theodoros Tzavaras ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Rheumatoid Arthritis Patient ◽  
Methotrexate Therapy ◽  
Patient Response ◽  
Flanking Region ◽  
Regulatory Polymorphism

scholarly journals Gynecomastia in a Rheumatoid Arthritis patient: A rare side effect of Methotrexate therapy. (Preprint)

2016 ◽  
Author(s):  
Soorih Shaikh ◽  
Sarwan Shaikh
Keyword(s):  
Rheumatoid Arthritis ◽  
Rheumatoid Arthritis Patient ◽  
Male Patient ◽  
Side Effect ◽  
Methotrexate Therapy ◽  
Folate Supplementation ◽  
Rare Side Effect ◽  
History Of ◽  
Male Patients

UNSTRUCTURED A 51-year-old male patient with a 3-year history of Rheumatoid Arthritis developed gynecomastia 2-3 months after starting Methotrexate therapy, without folate supplementation. Two months after stopping MTX therapy and initiating folate supplementation, gynecomastia started resolving. Very few cases of gynecomastia due to MTX therapy have been reported worldwide. Although it is a rare yet a significant occurrence and should always be considered in male patients with Rheumatoid Arthritis.

Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy

2004 ◽  
Vol 25 (4) ◽  
pp. 311-313 ◽  
Author(s):  
Byung-Ryul Choi ◽  
Myung-Ju Ahn ◽  
Woong Soo Lee ◽  
Tae-Hwan Kim ◽  
Sang-Cheol Bae ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Rheumatoid Arthritis Patient ◽  
Low Dose ◽  
Methotrexate Therapy ◽  
Dose Methotrexate
Sign in / Sign up

Export Citation Format

Share Document